Liquidia (NASDAQ:LQDA) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Liquidia (NASDAQ:LQDA) issued its quarterly earnings results on Wednesday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.07), Zacks reports. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%.

Liquidia Price Performance

LQDA stock opened at $14.74 on Wednesday. The firm’s fifty day simple moving average is $14.62 and its 200-day simple moving average is $12.10. The company has a market capitalization of $1.25 billion, a P/E ratio of -9.04 and a beta of 0.07. Liquidia has a 12 month low of $8.26 and a 12 month high of $16.99.

Analysts Set New Price Targets

LQDA has been the topic of a number of recent analyst reports. Wells Fargo & Company initiated coverage on shares of Liquidia in a research note on Friday, December 20th. They set an “overweight” rating and a $20.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $19.00 price target on shares of Liquidia in a research note on Thursday, January 9th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $25.38.

Insider Activity

In related news, General Counsel Russell Schundler sold 16,393 shares of the stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $193,109.54. Following the sale, the general counsel now directly owns 573,478 shares of the company’s stock, valued at approximately $6,755,570.84. This represents a 2.78 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Michael Kaseta sold 23,370 shares of the stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $275,298.60. Following the sale, the chief financial officer now directly owns 401,755 shares in the company, valued at $4,732,673.90. This trade represents a 5.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,245 shares of company stock valued at $843,326 in the last ninety days. Insiders own 30.10% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).